Literature DB >> 20237495

Enhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/hyaluronic acid correlates with downregulation of c-FLIP.

Lothar F Fecker1, Eggert Stockfleth, Frank K Braun, Paul M Rodust, Constanze Schwarz, Anja Köhler, Martin Leverkus, Jürgen Eberle.   

Abstract

Actinic keratosis (AK) occurs on sun-exposed skin and may progress to invasive squamous cell carcinoma (SCC). As for its topical treatment, diclofenac/hyaluronic acid (HA) has been recently approved. The NSAID diclofenac is an inhibitor of COX-2; however, its mode of action in cutaneous epithelial cancer cells is largely unknown. Here, the effects of diclofenac/HA were investigated in relation to death ligand-mediated apoptosis (TNF-alpha, TRAIL, and CD95 activation). Whereas diclofenac/HA only moderately induced apoptosis by itself, it resulted in pronounced enhancement of death ligand-mediated apoptosis in sensitive SCC cell lines (3/4). Apoptosis was associated with activation of initiator caspases of the extrinsic pathway (caspase-8/caspase-10). Furthermore, death ligand and diclofenac/HA-mediated apoptosis were blocked by the same caspase inhibitors, indicating related pathways. The proapoptotic effects of diclofenac/HA appeared independent of the p53 pathway. Also, upregulation of death receptors appeared less important; however, strong downregulation of c-FLIP isoforms was seen after diclofenac/HA treatment. The crucial role of c-FLIP was proven through overexpression and knockdown experiments. Thus, induction of apoptosis appears to be highly characteristic of the mode of action of diclofenac/HA, and the therapeutic effect may be related to sensitization of neoplastic keratinocytes for death ligand-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237495     DOI: 10.1038/jid.2010.40

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Effects of Non-Opioid Analgesics on the Cell Membrane of Skin and Gastrointestinal Cancers.

Authors:  Natalia Janicka; Agnieszka Sałek; Magdalena Sawińska; Ernest Kuchar; Anna Wiela-Hojeńska; Katarzyna Karłowicz-Bodalska
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

2.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

3.  Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-κB inhibitors in ovarian cancer therapy.

Authors:  Luiz F Zerbini; Rodrigo E Tamura; Ricardo G Correa; Akos Czibere; Jason Cordeiro; Manoj Bhasin; Fernando M Simabuco; Yihong Wang; Xuesong Gu; Linglin Li; Devanand Sarkar; Jin-Rong Zhou; Paul B Fisher; Towia A Libermann
Journal:  PLoS One       Date:  2011-09-12       Impact factor: 3.240

4.  Diclofenac gel in the treatment of actinic keratoses.

Authors:  Christopher G Nelson
Journal:  Ther Clin Risk Manag       Date:  2011-06-15       Impact factor: 2.423

5.  Role of CPI-17 in restoring skin homoeostasis in cutaneous field of cancerization: effects of topical application of a film-forming medical device containing photolyase and UV filters.

Authors:  Joan Anton Puig-Butillé; Josep Malvehy; Miriam Potrony; Carles Trullas; Francisco Garcia-García; Joaquin Dopazo; Susana Puig
Journal:  Exp Dermatol       Date:  2013-07       Impact factor: 3.960

Review 6.  Cyclooxygenase in Cancer Prevention and Treatments for Actinic Keratosis.

Authors:  Gareth J Thomas; Colin A Morton
Journal:  Dermatol Ther (Heidelb)       Date:  2017-02-01

7.  Cost-efficacy analysis of 3% diclofenac sodium, ingenol mebutate, and 3.75% imiquimod in the treatment of actinic keratosis.

Authors:  Steven Nisticò; Ester Del Duca; Valeria Torchia; Micaela Gliozzi; Ugo Bottoni; Carolina Muscoli
Journal:  Int J Immunopathol Pharmacol       Date:  2018 Jan-Dec       Impact factor: 3.219

Review 8.  Treatment of actinic keratosis through inhibition of cyclooxygenase-2: Potential mechanism of action of diclofenac sodium 3% in hyaluronic acid 2.5.

Authors:  Gareth J Thomas; Pedro Herranz; Susana Balta Cruz; Aurora Parodi
Journal:  Dermatol Ther       Date:  2019-04-09       Impact factor: 2.851

9.  New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel.

Authors:  Brian Berman
Journal:  Clin Cosmet Investig Dermatol       Date:  2012-08-24

10.  High ROS Production by Celecoxib and Enhanced Sensitivity for Death Ligand-Induced Apoptosis in Cutaneous SCC Cell Lines.

Authors:  Jiaqi Zhu; Stefanie May; Claas Ulrich; Eggert Stockfleth; Jürgen Eberle
Journal:  Int J Mol Sci       Date:  2021-03-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.